ABSTRACT
A recent analysis using family history weighting and co-observation classification modeling indicated that BRCA1 c.594-2A > C (IVS9-2A > C), previously described to cause exon 10 skipping (a truncating alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess pathogenicity of c.594-2A > C. The combined odds for causality considering case-control, segregation and breast tumor pathology information was 3.23 × 10-8 Our data indicate that c.594-2A > C is always in cis with c.641A > G. The spliceogenic effect of c.[594-2A > C;641A > G] was characterized using RNA analysis of human samples and splicing minigenes. As expected, c.[594-2A > C; 641A > G] caused exon 10 skipping, albeit not due to c.594-2A > C impairing the acceptor site but rather by c.641A > G modifying exon 10 splicing regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce detectable levels of full-length transcripts, with a per allele BRCA1 expression profile composed of ≈70-80% truncating transcripts, and ≈20-30% of in-frame Δ9,10 transcripts predicted to encode a BRCA1 protein with tumor suppression function.We confirm that BRCA1c.[594-2A > C;641A > G] should not be considered a high-risk pathogenic variant. Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of variants in disease-causing genes.
Subject(s)
BRCA1 Protein/genetics , Breast Neoplasms/genetics , Mutation/genetics , Ovarian Neoplasms/genetics , Tumor Suppressor Proteins/genetics , Adult , Aged , Alternative Splicing/genetics , Breast Neoplasms/pathology , DNA Mutational Analysis , Exons/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Middle Aged , Ovarian Neoplasms/pathology , RNA Splice Sites/genetics , RNA Splicing/geneticsABSTRACT
PURPOSE: Monoallelic germ-line deleterious mutations of PALB2 (partner and localizer of BRCA2) are associated with breast cancer risk and have been found in several populations, with carrier frequencies of ~1-2%. Initially, these mutations were considered to have moderate penetrance, but accumulating evidence now indicates that they are associated with much higher risk. METHODS: In this study, we sequenced the PALB2 coding regions unlinked to BRCA (breast cancer) genes in 575 probands from Italian breast cancer families recruited in Milan. RESULTS: We found 12 carriers (2.1%) of deleterious mutations, and none of the mutations was found in 784 controls collected in Milan. One of these mutations, the c.1027C>T (p.Gln343X), was found to be recurrent in the province of Bergamo in northern Italy, being detected in 6/113 (5.3%) familial breast cancer cases and 2/477 (0.4%) controls recruited in this area (Fisher's exact test: P < 0.01). CONCLUSIONS: Our data provide confirmatory findings that, in the Italian population also, deleterious mutations of PALB2 are relatively frequent predisposing factors for breast cancer and may be associated with high risk of the disease.
Subject(s)
Mutation , Nuclear Proteins/genetics , Tumor Suppressor Proteins/genetics , White People/genetics , Alleles , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Case-Control Studies , DNA Mutational Analysis , Fanconi Anemia Complementation Group N Protein , Female , Genetic Predisposition to Disease , Genotype , Humans , Italy , Polymorphism, GeneticABSTRACT
OBJECTIVES: Plasmodium gametocytes, responsible for malaria parasite transmission from humans to mosquitoes, represent a crucial target for new antimalarial drugs to achieve malaria elimination/eradication. We developed a novel colorimetric screening method for anti-gametocyte compounds based on the parasite lactate dehydrogenase (pLDH) assay, already standardized for asexual stages, to measure gametocyte viability and drug susceptibility. METHODS: Gametocytogenesis of 3D7 and NF54 Plasmodium falciparum strains was induced in vitro and asexual parasites were depleted with N-acetylglucosamine. Gametocytes were treated with dihydroartemisinin, epoxomicin, methylene blue, primaquine, puromycin or chloroquine in 96-well plates and the pLDH activity was evaluated using a modified Makler protocol. Mosquito infectivity was measured by the standard membrane feeding assay (SMFA). RESULTS: A linear correlation was found between gametocytaemia determined by Giemsa staining and pLDH activity. A concentration-dependent reduction in pLDH activity was observed after 72 h of drug treatment, whereas an additional 72 h of incubation without drugs was required to obtain complete inhibition of gametocyte viability. SMFA on treated and control gametocytes confirmed that a reduction in pLDH activity translates into reduced oocyst development in the mosquito vector. CONCLUSIONS: The gametocyte pLDH assay is fast, easy to perform, cheap and reproducible and is suitable for screening novel transmission-blocking compounds, which does not require parasite transgenic lines.
Subject(s)
Antimalarials/isolation & purification , Antimalarials/pharmacology , Cell Survival/drug effects , Drug Evaluation, Preclinical/methods , L-Lactate Dehydrogenase/analysis , Plasmodium falciparum/drug effects , Plasmodium falciparum/physiology , Animals , Colorimetry/methods , Humans , Plasmodium falciparum/enzymologySubject(s)
Breast Neoplasms/genetics , MicroRNAs/genetics , Australia , Case-Control Studies , Europe , Female , Genetic Predisposition to Disease , Genetic Variation , HumansABSTRACT
In malaria, the evidence concerning the nucleotide-binding, oligomerization domain (NOD) 2 (NOD2) receptor is fragmented and the stimuli that might activate NOD2 are not well characterized. We investigated the role of NOD2 in vitro in the response of macrophages to Plasmodium falciparum products. Immortalized or primary bone marrow derived macrophages from wild type C57Bl/6 mice, or knockout mice for NOD2 or its adaptor proteins, were either primed with interferon gamma or left untreated, and stimulated with parasite products. Both lysates of infected erythrocytes or hemozoin induced higher levels of nitric oxide in primed than in unprimed wild type macrophages. When stimulated with hemozoin, primed macrophages knockout for NOD2, or for its adaptor proteins, produced significantly lower nitric oxide levels compared to wild type cells. Differently from hemozoin, the use of ß-hematin (synthetic hemozoin) as stimulus showed that NOD2 is dispensable. Furthermore, the production of inflammatory cytokines by wild type cells treated with hemozoin was not dependent on NOD2. These data indicate that parasite components present in the hemozoin, differently from ß-hematin, induce the production of nitric oxide through the activation of NOD2, whereas the production of inflammatory cytokines, like TNF-α or MIP-2 (CXCL2), seems to be NOD2 independent.
Subject(s)
Hemeproteins/immunology , Malaria/immunology , Nod2 Signaling Adaptor Protein/immunology , Animals , Cytokines/metabolism , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout/immunologySubject(s)
Asymptomatic Infections/epidemiology , Betacoronavirus , Clinical Laboratory Techniques , Coronavirus Infections , Pandemics , Pneumonia, Viral , Adult , Antibodies, Viral/analysis , Betacoronavirus/immunology , Betacoronavirus/isolation & purification , COVID-19 , COVID-19 Testing , Child , Clinical Laboratory Techniques/methods , Clinical Laboratory Techniques/statistics & numerical data , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/physiopathology , Female , Humans , Italy/epidemiology , Male , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/physiopathology , Reproducibility of Results , SARS-CoV-2ABSTRACT
OBJECTIVES: The purpose of this paper was to determine whether microRNAs (miRNAs) involved in myocardial remodeling were differentially expressed in the blood of hypertrophic cardiomyopathy (HCM) patients, and whether circulating miRNAs correlated with the degree of left ventricular hypertrophy and fibrosis. BACKGROUND: miRNAs-small, noncoding ribonucleic acids (RNAs) that regulate gene expression by inhibiting RNA translation-modulate cellular function. Myocardial miRNAs modulate processes such as cardiomyocyte (CM) hypertrophy, excitation-contraction coupling, and apoptosis; non-CM-specific miRNAs regulate myocardial vascularization and fibrosis. Recently, the possibility that circulating miRNAs may be biomarkers of cardiovascular disease has been raised. METHODS: Forty-one HCM patients were characterized with conventional transthoracic echocardiography and cardiac magnetic resonance. Peripheral plasma levels of 21 miRNAs were assessed by quantitative real-time polymerase chain reaction and were compared with levels in a control group of 41 age- and sex-matched blood donors. RESULTS: Twelve miRNAs (miR-27a, -199a-5p, -26a, -145, -133a, -143, -199a-3p, -126-3p, -29a, -155, -30a, and -21) were significantly increased in HCM plasma. However, only 3 miRNAs (miR-199a-5p, -27a, and -29a) correlated with hypertrophy; more importantly, only miR-29a correlated also with fibrosis. CONCLUSIONS: Our data suggest that cardiac remodeling associated with HCM determines a significant release of miRNAs into the bloodstream: the circulating levels of both cardiac- and non-cardiac-specific miRNAs are significantly increased in the plasma of HCM patients. However, correlation with left ventricular hypertrophy parameters holds true for only a few miRNAs (i.e., miR-199a-5p, -27a, and -29a), whereas only miR-29a is significantly associated with both hypertrophy and fibrosis, identifying it as a potential biomarker for myocardial remodeling assessment in HCM.
Subject(s)
Biomarkers/blood , Cardiomyopathy, Hypertrophic/genetics , Hypertrophy, Left Ventricular/pathology , MicroRNAs/blood , Adult , Cardiomyopathy, Hypertrophic/blood , Echocardiography , Female , Fibrosis/blood , Fibrosis/genetics , Humans , Hypertrophy/blood , Hypertrophy/genetics , Magnetic Resonance Spectroscopy , Male , MicroRNAs/metabolism , Middle Aged , ROC Curve , Real-Time Polymerase Chain Reaction , Up-RegulationABSTRACT
Thyme essential oil and thymol have antimicrobial, antifungal and antioxidant activities. Their antioxidant activity has been studied almost exclusively by means of chemical testing in order to be able to use it for food preservation purposes. The aim of this luminol amplified chemiluminescence (LACL) study was to investigate whether thymol can interfere with the production of reactive oxygen species, nitric oxide and the nitric oxide-derived peroxynitrite released by human neutrophils after activation by fMLP and PMA with and without the addition of the L-arginine (L-Arg) nitric oxide donor to the medium. The lowest thymol concentration that was still active in reducing LACL was 2.73 microg/ml, and there was a progressive linear inhibition of LACL from this concentration to 21.87 microg/ml, the highest thymol concentration investigated. This was also observed in the case of both fMLP and PMA stimulation with or without L-Arg. In cell-free systems using H(2)O(2)/HOCl(-) and SIN-1 as radical producers, a significant scavenging activity of thymol was present already at 0.08 and 0.68 microg/ml respectively, and these are very low concentrations. These findings can be related to the phenolic structure of thymol, because phenolic compounds have redox properties and play an important role in adsorbing and neutralizing free radicals and peroxynitrite, and in decomposing peroxides. Our findings in human neutrophils are pharmacologically relevant as they imply that thymol is a potential antioxidant and anti-inflammatory agent in human cells.